BETA BIONICS INC
BBNXNASDAQTrading Snapshot
- Day Range
- $19.26 – $19.54
- 52-Week Range
- $8.80 – $32.71
- Volume
- $4.53B
- Avg Volume
- $4.85B
- Shares Outstanding
- 45.0M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $119M
- Last Q Revenue
- $33M
- P/E Ratio
- -12.8
- P/S Ratio
- 8.1x
- EPS (TTM)
- $-1.64
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −5.4%
Why Investors Own BBNX
- ✓High-growth profile — revenue up +16.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 54% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BETA BIONICS INC
BBNX
StockOtter · stockotter.spaceAbout BETA BIONICS INC
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
BETA BIONICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift BBNX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
BETA BIONICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.